Overview

Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
Phase:
Phase 1
Details
Lead Sponsor:
Novartis